Bacterial Vaccines

• 

  Subject Areas on Research

  • A need for effective adjuvants. 
  • A novel neurotoxoid vaccine prevents mucosal botulism. 
  • Active immunotherapy for TNF-mediated inflammation using self-assembled peptide nanofibers. 
  • Anti-polyribosylribitol phosphate antibody levels 5 years after a primary series of Haemophilus influenzae type B conjugate vaccine. 
  • Antibody response of 18 month old children 1 month and 18 months following Haemophilus influenzae type b vaccine administered singly or with DTP vaccine. 
  • Bacterial meningitis in infants. 
  • Bacteriotherapy for clostridium difficile colitis. 
  • Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. 
  • Childhood vaccine development: an overview. 
  • Clostridium Difficile Infection from a Surgical Perspective. 
  • Comparison of active and combined passive/active immunization of Navajo children against Haemophilus influenzae type b. 
  • Control of meningococcal disease in west Africa. 
  • Controversies in immunization. 
  • Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression. 
  • Defining Potential Vaccine Targets of Haemophilus ducreyi Trimeric Autotransporter Adhesin DsrA. 
  • Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. 
  • Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1. 
  • Emergency vaccination against epidemic meningitis in Ghana: implications for the control of meningococcal disease in West Africa. 
  • Enhanced priming of adaptive immunity by Mycobacterium smegmatis mutants with high-level protein secretion. 
  • From the Centers for Disease Control and Prevention. Surveillance for adverse effects associated with anthrax vaccination--US Department of Defense, 1998-2000. 
  • Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env. 
  • Haemophilus influenzae type b infection after nephrotic syndrome in a previously vaccinated child. 
  • IFN-γ, but not IL-17A, is required for survival during secondary pulmonary Francisella tularensis Live Vaccine Stain infection. 
  • Identification of a second family of high-molecular-weight adhesion proteins expressed by non-typable Haemophilus influenzae. 
  • Identification of population at risk for future Clostridium difficile infection following hospital discharge to be targeted for vaccine trials. 
  • Immunisation for the prevention of Haemophilus influenzae type b infections: a review. 
  • Immunization against Haemophilus influenzae. 
  • Immunization with the Haemophilus ducreyi hemoglobin receptor HgbA with adjuvant monophosphoryl lipid A protects swine from a homologous but not a heterologous challenge. 
  • Immunization with the Haemophilus ducreyi trimeric autotransporter adhesin DsrA with alum, CpG or imiquimod generates a persistent humoral immune response that recognizes the bacterial surface. 
  • Immunizations for preteens. 
  • Immunogenicity of Haemophilus b conjugate vaccine (meningococcal protein conjugate) in children with prior invasive Haemophilus influenzae type b disease. 
  • Impaired immune response of splenectomised patients to polyvalent pneumococcal vaccine. 
  • Infection with Francisella tularensis LVS clpB leads to an altered yet protective immune response. 
  • Intranasal vaccination with the recombinant Listeria monocytogenes ΔactA prfA* mutant elicits robust systemic and pulmonary cellular responses and secretory mucosal IgA. 
  • Invasive gram-positive bacterial infection in cancer patients. 
  • Lyme disease vaccination: are we ready to try again? 
  • Lyme disease vaccination: safety first - author's reply. 
  • Meningococcal immunisation in Ghana. 
  • Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits. 
  • Non-specific and specific active immunotherapy in a B16 murine melanoma system. 
  • Organ distribution of Corynebacterium parvum labeled with iodine-125. 
  • Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine Efficacy. 
  • Pneumococcal vaccine administration associated with splenectomy: the need for improved education, documentation, and the use of a practical checklist. 
  • Preparation and preclinical evaluation of a novel liposomal complete-core lipopolysaccharide vaccine. 
  • Protection against Mycobacterium avium by DNA vaccines expressing mycobacterial antigens as fusion proteins with green fluorescent protein. 
  • Recent changes in vaccination guidelines. An update on vaccines and target population initiatives. 
  • Recombinant BCG Expressing Mycobacterium ulcerans Ag85A Imparts Enhanced Protection against Experimental Buruli ulcer. 
  • Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. 
  • Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages, and derived cytokines following oral immunization with live recombinant Salmonella. 
  • Reimmunization to pneumococcus in patients with sickle cell disease: do they or don't they respond? 
  • Rhipicephalus sanguineus: vector of a new spotted fever group rickettsia in the United States. 
  • Serotype-specific immunoglobulin G antibody responses to pneumococcal polysaccharide vaccine in children with sickle cell anemia: effects of continued penicillin prophylaxis. 
  • Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. 
  • T-independent activation-induced cytidine deaminase expression, class-switch recombination, and antibody production by immature/transitional 1 B cells. 
  • The Haemophilus ducreyi trimeric autotransporter adhesin DsrA protects against an experimental infection in the swine model of chancroid. 
  • The biological activity of a liposomal complete core lipopolysaccharide vaccine. 
  • The development of therapeutic and preventive vaccines for gastric cancer and Helicobacter pylori. 
  • Therapeutic strategies to combat pneumococcal disease: repeated failure of physicians to adopt pneumococcal vaccine, 1900-1945. 
• 

  Keywords of People

  • Kelsoe, Garnett H., James B. Duke Professor of Immunology, Immunology